All In Biotech

Drug Trial Radar · NCT04939441

Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)

Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 240 Weeks Open-label Multicenter Study

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 20, 2021

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Jidong JiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Ditan Hospital; ShuGuang Hospital; Huashan Hospital; Tianjin Second People's Hospital; Ruijin Hospital; Tianjin Third Central Hospital; The Ninth Hospital of Nanchang; Beijing YouAn Hospital; The Fifth People's Hospital of Suzhou
First posted
Jun 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven significant fibrosis (METAVIR fibrosis stage ≥ F2). To characterize longitudinal histological changes and assess liver fibrosis regression, the second and third liver biopsies are planned at weeks 96 and 240, respectively. During this study, all subjects will be assessed for laboratory tests, imaging examination at baseline, first 12-week and every 24-week during follow-up.

Conditions

  • Chronic Hepatitis B

Interventions

  • Tenofovir alafenamideDrug

    Subjects will be treated for 240 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with fibrosis regressionTime frame: Week 96 and 240
  2. HBV DNA undetectable rateTime frame: Week 96

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing YouAn Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The Fifth People's Hospital of Suzhou

    Suzhou, Jiangsu, China · Recruiting

  • The Ninth Hospital of Nanchang

    Nanchang, Jiangxi, China · Recruiting

  • Shuguang Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Ruijin Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Third Central Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Tianjin Second People's Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.